Murphy, Lara E.
Fonseka, Trehani M.
Bousman, Chad A. http://orcid.org/0000-0001-6303-8696
Müller, Daniel J. http://orcid.org/0000-0003-4978-4400
Article History
Received: 13 May 2021
Revised: 23 September 2021
Accepted: 1 October 2021
First Online: 9 November 2021
Competing interests
: DJM and CAB are members of the Clinical Pharmacogenomics Implementation Consortium. TMF and LEM have no conflicts to declare. DJM was a co-investigator on two pharmacogenetic studies where genetic test kits were provided as in-kind contributions by Myriad Neuroscience. DJM did not receive any payments or any equity, stocks, or options from any pharmacogenetic companies. DJM is also a co-inventor on two patents assessing risk for antipsychotic-induced weight gain (pending). CAB is founder and equity holder in Sequence2Script Inc.